MA33659B1 - Dihydrobenzocycloalkyl-oxyméthyl-oxazolopyrimidinones substituées, préparation et utilisation de celles-ci - Google Patents
Dihydrobenzocycloalkyl-oxyméthyl-oxazolopyrimidinones substituées, préparation et utilisation de celles-ciInfo
- Publication number
- MA33659B1 MA33659B1 MA34754A MA34754A MA33659B1 MA 33659 B1 MA33659 B1 MA 33659B1 MA 34754 A MA34754 A MA 34754A MA 34754 A MA34754 A MA 34754A MA 33659 B1 MA33659 B1 MA 33659B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- present
- oxzolopperidinone
- oxymetil
- dihydrobenzocycloacyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000022925 sleep disturbance Diseases 0.000 abstract 1
- 230000008673 vomiting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La présente invention concerne une série de dihydro-benzocycloalkyl-oxyméthyl-oxazolopyrimidinones substituées de formule (I), comme définie ici. L'invention concerne également des procédés de fabrication desdits composés, dont des intermédiaires inédits. Les composés de la présente invention sont des modulateurs des récepteurs métabotropiques du glutamate (mGluR) et, en particulier, du récepteur mGluR2. En conséquence, les composés de la présente invention peuvent être utilisés en tant qu'agents pharmaceutiques, en particulier dans le cadre du traitement et/ou de la prévention de diverses affections du système nerveux central (SNC), dont, mais la liste n'est pas limitative, les affections neurodégénératives aiguës et chroniques, les psychoses, le déficit cognitif, les convulsions, l'anxiété, la dépression, la migraine, la douleur, les troubles du sommeil et les vomissements.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24258609P | 2009-09-15 | 2009-09-15 | |
| FR1055806 | 2010-07-16 | ||
| PCT/US2010/048695 WO2011034830A1 (fr) | 2009-09-15 | 2010-09-14 | Dihydro-benzocycloalkyl-oxyméthyl-oxazolopyrimidinones substituées, leur préparation et leur utilisation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA33659B1 true MA33659B1 (fr) | 2012-10-01 |
Family
ID=43003494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA34754A MA33659B1 (fr) | 2009-09-15 | 2012-04-04 | Dihydrobenzocycloalkyl-oxyméthyl-oxazolopyrimidinones substituées, préparation et utilisation de celles-ci |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9051331B2 (fr) |
| EP (1) | EP2477994B1 (fr) |
| JP (1) | JP5628320B2 (fr) |
| KR (1) | KR101721423B1 (fr) |
| CN (1) | CN102498116B (fr) |
| AR (1) | AR078171A1 (fr) |
| AU (1) | AU2010295802B2 (fr) |
| BR (1) | BR112012005736A2 (fr) |
| CA (1) | CA2773555C (fr) |
| CO (1) | CO6511237A2 (fr) |
| DK (1) | DK2477994T3 (fr) |
| ES (1) | ES2451348T3 (fr) |
| IL (1) | IL218490A (fr) |
| MA (1) | MA33659B1 (fr) |
| MX (1) | MX2012002725A (fr) |
| NZ (1) | NZ598743A (fr) |
| PT (1) | PT2477994E (fr) |
| RU (1) | RU2543384C2 (fr) |
| SG (1) | SG178997A1 (fr) |
| TW (1) | TWI495639B (fr) |
| UY (1) | UY32888A (fr) |
| WO (1) | WO2011034830A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| NZ579431A (en) | 2007-03-09 | 2012-04-27 | Sanofi Aventis | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof |
| EA017648B1 (ru) | 2007-09-14 | 2013-02-28 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2н,1'н-[1,4']бипириди-нил-2'-оны |
| BRPI0816970A2 (pt) | 2007-09-14 | 2015-03-24 | Ortho Mcneil Janssen Pharm | 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas |
| JP5547194B2 (ja) | 2008-09-02 | 2014-07-09 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体 |
| WO2010043396A1 (fr) | 2008-10-16 | 2010-04-22 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Dérivés d’indole et de benzomorpholine en tant que modulateurs des récepteurs métabotropiques du glutamate |
| JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ， インコーポレイテッド． | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
| CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| HRP20131122T1 (hr) | 2009-05-12 | 2013-12-20 | Janssen Pharmaceuticals, Inc. | Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja |
| JP5852664B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
| ES2536433T3 (es) | 2010-11-08 | 2015-05-25 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
| EP2661435B1 (fr) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | Dérivés 1,2,4-triazolo[4,3-a]pyridine et leur utilisation en tant que modulateurs allostériques positifs des récepteurs mglur2 |
| JP2015006994A (ja) * | 2011-10-28 | 2015-01-15 | 大正製薬株式会社 | ジヒドロイミダゾオキサゾール誘導体 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| ME03518B (fr) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Combinaisons comprenant des modulateurs allostériques positifs de sous-type 2 de récepteurs glutamatergiques métabotropes et leur utilisation |
| PL3096790T3 (pl) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH517066A (de) | 1969-07-09 | 1971-12-31 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Aryloxy- und Arylthioessigsäuren und ihren Alkali- und Erdalkalimetallsalzen |
| FR2724171B1 (fr) | 1994-09-05 | 1997-01-03 | Synthelabo | Derives de 3,3a,4,5-tetrahydro-1h-oxazolo(3,4-a)quinolein-1-one, leur preparation et leur application en therapeutique |
| DE19801646A1 (de) * | 1998-01-17 | 1999-07-22 | Bayer Ag | Substituierte alpha,beta-annellierte Butyrolactone |
| HUP0303270A3 (en) | 2001-02-21 | 2007-03-28 | Janssen Pharmaceutica Nv | Isoxazoline derivatives as anti-depressants, process for their preparation and pharmaceutical compositions containing them |
| US7476673B2 (en) | 2003-12-30 | 2009-01-13 | Allergan, Inc. | Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors |
| ATE383361T1 (de) * | 2004-06-21 | 2008-01-15 | Hoffmann La Roche | Pyrrazolopyrimidinderivate |
| CN101087771A (zh) | 2004-11-10 | 2007-12-12 | 辉瑞大药厂 | 经取代n－磺酰基氨基苄基－2－苯氧基乙酰胺化合物 |
| NZ579431A (en) * | 2007-03-09 | 2012-04-27 | Sanofi Aventis | Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof |
| EP2268645B1 (fr) * | 2008-03-06 | 2014-11-12 | Sanofi | Dihydro-, trihydro- et tétrahydro- cycloalkyloxazolopyrimidinones substituées, préparation et utilisation de celles-ci en tant que modulateurs allostériques de mglur |
| AR078173A1 (es) * | 2009-09-15 | 2011-10-19 | Sanofi Aventis | Bifeniloximetil dihidro oxazolopirimidinonas sustituidas, su preparacion y su uso |
| AR078172A1 (es) * | 2009-09-15 | 2011-10-19 | Sanofi Aventis | Fenoximetil dihidro oxazolopirimidinonas sustituidas y uso de las mismas como moduladores de receptores metabotropicos de mglur |
-
2010
- 2010-09-13 AR ARP100103337A patent/AR078171A1/es not_active Application Discontinuation
- 2010-09-14 RU RU2012114602/04A patent/RU2543384C2/ru not_active IP Right Cessation
- 2010-09-14 WO PCT/US2010/048695 patent/WO2011034830A1/fr not_active Ceased
- 2010-09-14 SG SG2012015491A patent/SG178997A1/en unknown
- 2010-09-14 NZ NZ598743A patent/NZ598743A/xx not_active IP Right Cessation
- 2010-09-14 PT PT107573461T patent/PT2477994E/pt unknown
- 2010-09-14 ES ES10757346.1T patent/ES2451348T3/es active Active
- 2010-09-14 BR BR112012005736A patent/BR112012005736A2/pt not_active IP Right Cessation
- 2010-09-14 JP JP2012529822A patent/JP5628320B2/ja not_active Expired - Fee Related
- 2010-09-14 CA CA2773555A patent/CA2773555C/fr not_active Expired - Fee Related
- 2010-09-14 EP EP10757346.1A patent/EP2477994B1/fr active Active
- 2010-09-14 DK DK10757346.1T patent/DK2477994T3/en active
- 2010-09-14 MX MX2012002725A patent/MX2012002725A/es active IP Right Grant
- 2010-09-14 CN CN201080041010.XA patent/CN102498116B/zh not_active Expired - Fee Related
- 2010-09-14 AU AU2010295802A patent/AU2010295802B2/en not_active Ceased
- 2010-09-14 TW TW099130956A patent/TWI495639B/zh not_active IP Right Cessation
- 2010-09-14 KR KR1020127006839A patent/KR101721423B1/ko not_active Expired - Fee Related
- 2010-09-15 UY UY0001032888A patent/UY32888A/es not_active Application Discontinuation
-
2012
- 2012-03-02 US US13/410,723 patent/US9051331B2/en not_active Expired - Fee Related
- 2012-03-05 IL IL218490A patent/IL218490A/en not_active IP Right Cessation
- 2012-03-14 CO CO12044041A patent/CO6511237A2/es active IP Right Grant
- 2012-04-04 MA MA34754A patent/MA33659B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR078171A1 (es) | 2011-10-19 |
| EP2477994B1 (fr) | 2013-12-11 |
| SG178997A1 (en) | 2012-04-27 |
| BR112012005736A2 (pt) | 2016-03-08 |
| RU2543384C2 (ru) | 2015-02-27 |
| AU2010295802B2 (en) | 2014-09-11 |
| CA2773555A1 (fr) | 2011-03-24 |
| UY32888A (es) | 2011-04-29 |
| JP5628320B2 (ja) | 2014-11-19 |
| US9051331B2 (en) | 2015-06-09 |
| AU2010295802A1 (en) | 2012-04-05 |
| WO2011034830A1 (fr) | 2011-03-24 |
| JP2013504622A (ja) | 2013-02-07 |
| KR20120068005A (ko) | 2012-06-26 |
| DK2477994T3 (en) | 2014-03-17 |
| CN102498116B (zh) | 2014-08-06 |
| CN102498116A (zh) | 2012-06-13 |
| MX2012002725A (es) | 2013-05-28 |
| TWI495639B (zh) | 2015-08-11 |
| NZ598743A (en) | 2013-02-22 |
| RU2012114602A (ru) | 2013-10-27 |
| IL218490A0 (en) | 2012-04-30 |
| PT2477994E (pt) | 2014-03-13 |
| CA2773555C (fr) | 2014-01-28 |
| KR101721423B1 (ko) | 2017-03-30 |
| US20120184566A1 (en) | 2012-07-19 |
| TW201121977A (en) | 2011-07-01 |
| ES2451348T3 (es) | 2014-03-26 |
| EP2477994A1 (fr) | 2012-07-25 |
| IL218490A (en) | 2015-05-31 |
| CO6511237A2 (es) | 2012-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG178997A1 (en) | Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof | |
| MX2009009447A (es) | Dihidro y tetrahidro oxazolopirimidinonas sustituidas, preparacion y uso de las mismas. | |
| MA30289B1 (fr) | Dérivés d'amines | |
| MX2011003691A (es) | Derivados de indol y benzomorfolina como moduladores de los receptores de glutamato metabotropico. | |
| MA32627B1 (fr) | Derive d'amides heteroaryliques et leur utilisation comme activateurs de glucokinase | |
| TW200634016A (en) | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | |
| MX2010002537A (es) | 4-fenil-1h-piridin-2-onas 1,3-disubstituidas. | |
| MX2010002538A (es) | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disubstituidas. | |
| MA31373B1 (fr) | Composes amino-heterocycliques | |
| MY152078A (en) | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones | |
| EA200801934A1 (ru) | 1,4-двузамещённые 3-циано-пиридоновые производные и их применение в качестве позитивных модуляторов рецепторов mglur2 | |
| MA32466B1 (fr) | Derives de triazole utiles pour le traitement de maladies | |
| MA43756B1 (fr) | Modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine | |
| MX2011005242A (es) | Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos. | |
| UA98098C2 (ru) | ПРОИЗВОДНЫЕ ПИРИДИНОНА И ИХ ПРИМЕНЕНИЕ КАК ПОЛОЖИТЕЛЬНЫХ АЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 | |
| MA33920B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide | |
| MA33134B1 (fr) | Derives d'indole en tant qu'antagonistes du recepteur crth2 | |
| WO2008050341A3 (fr) | Agents psychotropes innovants présentant une activité du glutamate sur les récepteurs nmda | |
| TN2010000230A1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| MX2015011313A (es) | Compuestos perfluorados de 5,6-dihidro-4h-1,3-oxazin-2-amina como inhibidores de beta-secretasa y metodos de uso. | |
| MX2009012608A (es) | Compuestos de hidroxietil amina substituidos como moduladores de beta-secretasa y metodos de uso. | |
| MA35874B1 (fr) | Dérivés d'amide cycliques à utiliser en tant qu'inhibiteurs de 11-bêta-hydroxystéroïde déshydrogénase et utilisations de ceux-ci | |
| MA32781B1 (fr) | Arycyclohexylethers de dihydrotetrazabenzoazulenes pour emploi en tant qu'antagonistes du recepteur v1a de la vasopressine | |
| MA38217A1 (fr) | Nouveaux dérivés de pyrazine comme agonistes des récepteurs cb2 | |
| MA33824B1 (fr) | Agonistes du recepteur mglu2 |